Atopic Dermatitis | Regeneron | SOLO 2
Pharmaceutical Company/Sponsor:
Regeneron
Code:
SOLO 2
Title:
A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic
Type:
Phase:
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Status:
Completed
Link for Additional Information:
